Treatment of Advanced Ovarian Cancer, with Thomas Herzog, MD: Case 1
Treatment of Advanced Ovarian Cancer, with Thomas Herzog, MD
Advertisement
May 2015
A 56-year-old woman presented to her gynecologist with urinary frequency and persistent abdominal bloating. The patient reports maintaining normal activities and a moderate exercise.
PMH: Hypertension, well-controlled or spironolactone
Abdominal ultrasound showed a complex mass in the right pelvis measuring 4.5 X 5.0 X 7.5 cm
Physical exam: fluid wave test positive for ascites
CA-125, 622 U/ml
She was referred to a gynecologic oncologist for further evaluation.
CT of the pelvis and abdomen showed a right complex pelvic mass, ascites, and omental cake. No other peritoneal lesions were visualized.
Based on CT findings, she was scheduled for surgery.
The patient underwent complete resection with no residual disease remaining.
Diagnosis, epithelial ovarian cancer, stage IIIC
She received 6 cycles of carboplatin every 3 weeks (AUC 6) and weekly paclitaxel (80 mg/m2) for 18 weeks.
Follow up labs showed normalization of CA-125 to less than 10 U/ml
April 2017
Almost 2 years later, the patient reported having symptoms of persistent abdominal distention and weight loss. She reports feeling tired and napping during the day.
CA-125 level, 330 U/ml
CT scan showed peritoneal seeding consistent with carcinomatosis
Diagnosis: platinum-sensitive recurrent ovarian cancer
The patient was started on bevacizumab (15 mg/kg) plus 6 cycles of carboplatin (AUC 5) and paclitaxel (175 mg/m2) every 3 weeks with a plan for bevacizumab maintenance therapy.
After 2 cycles of therapy, she developed grade 2 hypertension (156/94 mm Hg); this was subsequently controlled by adding an ACE inhibitor to her diuretic.
The patient has continued therapy without incident.
Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).
Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.
The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.
Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.